Form 4: Assembly Biosciences Director Houghton Granted Stock Options
SEC Form 4 Filing
Director Michael Houghton of Assembly Biosciences, Inc. was granted stock options to purchase 2,750 shares of common stock on May 29, 2024.
Summary
- Michael Houghton, a director of Assembly Biosciences, Inc., was granted stock options on May 29, 2024.
- The options allow Houghton to purchase 2,750 shares of Assembly Biosciences' common stock at an exercise price of $15.06 per share.
- The stock options vest on the earlier of May 29, 2025, or the date of the Issuer's 2025 annual meeting of stockholders, assuming continuous service.
- The options expire on May 29, 2034.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and indicates confidence in the director's continued service and contribution to the company's success.
Positives
- The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.
Future Outlook
The document does not contain specific forward-looking statements regarding the company's future performance, but the stock option grant suggests an expectation of continued service from the director.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company. This is a standard compensation practice.
Comparison to Industry Standards
- Stock option grants are a typical component of executive compensation packages in the biotech industry.
- Companies like Gilead Sciences, Amgen, and Biogen also use stock options to incentivize their directors and officers.
- The vesting schedule and exercise price are generally determined based on industry benchmarks and the individual's contribution to the company.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it aligns the director's interests with the company's long-term performance.
- The director is incentivized to contribute to the company's success to increase the value of their stock options.
Key Dates
| Date | Description |
|---|---|
| 05/29/2024 | Date of stock option grant and transaction date. |
| 05/29/2025 | First possible vesting date of the stock options. |
| May 2025 | Second possible vesting date of the stock options, dependent on the date of the Issuer's 2025 annual meeting of stockholders. |
| 05/29/2034 | Expiration date of the stock options. |
| 05/30/2024 | Date of signature of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.